Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy

Kuangda Lu, Chunbai He, Nining Guo, Christina Chan, Kaiyuan Ni, Guangxu Lan, Haidong Tang, Charles Pelizzari, Yang Xin Fu, Michael T. Spiotto, Ralph R. Weichselbaum, Wenbin Lin

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Checkpoint blockade immunotherapy relies on energized cytotoxic T cells attacking tumour tissue systemically. However, for many cancers, the reliance on T cell infiltration leads to low response rates. Conversely, radiotherapy has served as a powerful therapy for local tumours over the past 100 years, yet is rarely sufficient to cause systemic tumour rejection. Here, we describe a treatment strategy that combines nanoscale metal–organic framework (nMOF)-enabled radiotherapy–radiodynamic therapy with checkpoint blockade immunotherapy for both local and systemic tumour elimination. In mouse models of breast and colorectal cancer, intratumorally injected nMOFs treated with low doses of X-ray irradiation led to the eradication of local tumours and, when loaded with an inhibitor of the immune checkpoint molecule indoleamine 2,3-dioxygenase, the irradiated nMOFs led to consistent abscopal responses that rejected distal tumours. By combining the advantages of local radiotherapy and systemic tumour rejection via synergistic X-ray-induced in situ vaccination and indoleamine 2,3-dioxygenase inhibition, nMOFs may overcome some of the limitations of checkpoint blockade in cancer treatment.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalNature Biomedical Engineering
DOIs
StateAccepted/In press - Mar 26 2018

Fingerprint

X-Ray Therapy
Immunotherapy
Dosimetry
Tumors
X rays
Neoplasms
Indoleamine-Pyrrole 2,3,-Dioxygenase
T-cells
Radiotherapy
Oncology
X-Rays
T-Lymphocytes
Infiltration
Therapeutics
Irradiation
Tissue
Colorectal Neoplasms
Vaccination
Molecules
Breast Neoplasms

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Computer Science Applications

Cite this

Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. / Lu, Kuangda; He, Chunbai; Guo, Nining; Chan, Christina; Ni, Kaiyuan; Lan, Guangxu; Tang, Haidong; Pelizzari, Charles; Fu, Yang Xin; Spiotto, Michael T.; Weichselbaum, Ralph R.; Lin, Wenbin.

In: Nature Biomedical Engineering, 26.03.2018, p. 1-11.

Research output: Contribution to journalArticle

Lu, Kuangda ; He, Chunbai ; Guo, Nining ; Chan, Christina ; Ni, Kaiyuan ; Lan, Guangxu ; Tang, Haidong ; Pelizzari, Charles ; Fu, Yang Xin ; Spiotto, Michael T. ; Weichselbaum, Ralph R. ; Lin, Wenbin. / Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. In: Nature Biomedical Engineering. 2018 ; pp. 1-11.
@article{07e11f3b1b4f401b86541ce01b93cf10,
title = "Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy",
abstract = "Checkpoint blockade immunotherapy relies on energized cytotoxic T cells attacking tumour tissue systemically. However, for many cancers, the reliance on T cell infiltration leads to low response rates. Conversely, radiotherapy has served as a powerful therapy for local tumours over the past 100 years, yet is rarely sufficient to cause systemic tumour rejection. Here, we describe a treatment strategy that combines nanoscale metal–organic framework (nMOF)-enabled radiotherapy–radiodynamic therapy with checkpoint blockade immunotherapy for both local and systemic tumour elimination. In mouse models of breast and colorectal cancer, intratumorally injected nMOFs treated with low doses of X-ray irradiation led to the eradication of local tumours and, when loaded with an inhibitor of the immune checkpoint molecule indoleamine 2,3-dioxygenase, the irradiated nMOFs led to consistent abscopal responses that rejected distal tumours. By combining the advantages of local radiotherapy and systemic tumour rejection via synergistic X-ray-induced in situ vaccination and indoleamine 2,3-dioxygenase inhibition, nMOFs may overcome some of the limitations of checkpoint blockade in cancer treatment.",
author = "Kuangda Lu and Chunbai He and Nining Guo and Christina Chan and Kaiyuan Ni and Guangxu Lan and Haidong Tang and Charles Pelizzari and Fu, {Yang Xin} and Spiotto, {Michael T.} and Weichselbaum, {Ralph R.} and Wenbin Lin",
year = "2018",
month = "3",
day = "26",
doi = "10.1038/s41551-018-0203-4",
language = "English (US)",
pages = "1--11",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy

AU - Lu, Kuangda

AU - He, Chunbai

AU - Guo, Nining

AU - Chan, Christina

AU - Ni, Kaiyuan

AU - Lan, Guangxu

AU - Tang, Haidong

AU - Pelizzari, Charles

AU - Fu, Yang Xin

AU - Spiotto, Michael T.

AU - Weichselbaum, Ralph R.

AU - Lin, Wenbin

PY - 2018/3/26

Y1 - 2018/3/26

N2 - Checkpoint blockade immunotherapy relies on energized cytotoxic T cells attacking tumour tissue systemically. However, for many cancers, the reliance on T cell infiltration leads to low response rates. Conversely, radiotherapy has served as a powerful therapy for local tumours over the past 100 years, yet is rarely sufficient to cause systemic tumour rejection. Here, we describe a treatment strategy that combines nanoscale metal–organic framework (nMOF)-enabled radiotherapy–radiodynamic therapy with checkpoint blockade immunotherapy for both local and systemic tumour elimination. In mouse models of breast and colorectal cancer, intratumorally injected nMOFs treated with low doses of X-ray irradiation led to the eradication of local tumours and, when loaded with an inhibitor of the immune checkpoint molecule indoleamine 2,3-dioxygenase, the irradiated nMOFs led to consistent abscopal responses that rejected distal tumours. By combining the advantages of local radiotherapy and systemic tumour rejection via synergistic X-ray-induced in situ vaccination and indoleamine 2,3-dioxygenase inhibition, nMOFs may overcome some of the limitations of checkpoint blockade in cancer treatment.

AB - Checkpoint blockade immunotherapy relies on energized cytotoxic T cells attacking tumour tissue systemically. However, for many cancers, the reliance on T cell infiltration leads to low response rates. Conversely, radiotherapy has served as a powerful therapy for local tumours over the past 100 years, yet is rarely sufficient to cause systemic tumour rejection. Here, we describe a treatment strategy that combines nanoscale metal–organic framework (nMOF)-enabled radiotherapy–radiodynamic therapy with checkpoint blockade immunotherapy for both local and systemic tumour elimination. In mouse models of breast and colorectal cancer, intratumorally injected nMOFs treated with low doses of X-ray irradiation led to the eradication of local tumours and, when loaded with an inhibitor of the immune checkpoint molecule indoleamine 2,3-dioxygenase, the irradiated nMOFs led to consistent abscopal responses that rejected distal tumours. By combining the advantages of local radiotherapy and systemic tumour rejection via synergistic X-ray-induced in situ vaccination and indoleamine 2,3-dioxygenase inhibition, nMOFs may overcome some of the limitations of checkpoint blockade in cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85044465726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044465726&partnerID=8YFLogxK

U2 - 10.1038/s41551-018-0203-4

DO - 10.1038/s41551-018-0203-4

M3 - Article

C2 - 31015630

AN - SCOPUS:85044465726

SP - 1

EP - 11

JO - Nature Biomedical Engineering

JF - Nature Biomedical Engineering

SN - 2157-846X

ER -